Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

Cytovance Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Dr. Jeffrey Su as Vice President of Bioanalytical Development to its diverse and growing scientific staff. Dr. Su will head up the state of the art Bioanalytical Development laboratory supporting existing and new client needs.

1 Sep 2009

D3 Ultra DFA Respiratory Virus Identification Kit can be used for detecting H1N1 virus

Diagnostic HYBRIDS announced that the US Food and Drug Administration has cleared an additional claim for the company's D3 Ultra DFA Respiratory Virus Identification Kit, which confirms that the assay can detect the 2009 influenza A (H1N1)v virus.

31 Aug 2009

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

Fernando Pisani and 24 hockey players helped raise funds and awareness about Crohn's disease and ulcerative colitis

The spirit of giving back was as strong as ever this weekend at the first ever Score for Colitis & Crohn's event, which raised $20,000 for four gastrointestinal and digestive disease patient organizations from across the country. The Score for Colitis & Crohn's initiative, which took place at the West Edmonton Mall's Ice Palace on Saturday, August 29th, featured Fernando Pisani of the Edmonton Oilers and 24 aspiring young hockey enthusiasts who were all on hand to help raise funds and awareness about Crohn's disease and ulcerative colitis, the latter of which Pisani was diagnosed with in 2007.

31 Aug 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million and recorded a loss before tax of DKK 188 million. As of 30 June 2009 the Group's net free liquidity was DKK 489 million.

28 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

AVANIR raises funds to develop and commercialize Zenvia for PBA

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced it had raised gross proceeds of approximately $10.6 million via the sale of approximately 4.5 million shares of common stock at a weighted average price of $2.34 per share.

28 Aug 2009

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

27 Aug 2009

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.

27 Aug 2009

IVD labeled staining reagents for manual and automated staining platforms from DBS

Diagnostic Biosystems (DBS), a specialty immunohistochemistry (IHC) reagent company, announces the availability of products for clinical use in the US.

27 Aug 2009

Anti-glycan antibody positivity observed in celiac disease

Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet. The importance of newly discovered inflammatory bowel disease-associated antibodies (including anti-glycan antibodies and anti-OMP) in celiac disease is not sure.

26 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

Tripep and the German biotech company Cosmix AG have both licensed their respective technologies (RAS and mRNA Display Library) to a newly formed US company named Opsonic Therapeuticals Inc. within which Tripep’s RAS technology will be developed.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, is accepting grant applications for a new initiative to establish a consortium of human immune profiling research centers.

25 Aug 2009

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Lpath, Inc., the category leader in lipidomics-based therapeutics, demonstrated commercially acceptable yields in its optimized fermentation process. In doing so, Lpath achieved one of four Phase 1 objectives established by Merck Serono, the exclusive worldwide licensee of ASONEP and Lpath's development partner, and will receive a milestone payment according to the terms of the Merck Serono license agreement.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Research reveals that diarrheal bacteria can cause colon cancers

Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. The investigators say that strains of the common Bacteroides fragilis (ETBF) dupe immune system cells into permitting runaway colon tissue inflammation, a precursor for malignant growth.

24 Aug 2009

Antibody News and Research

Further Reading

New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

D3 Ultra DFA Respiratory Virus Identification Kit can be used for detecting H1N1 virus

MabCure featured in the August edition of Biotechnology Focus magazine

Fernando Pisani and 24 hockey players helped raise funds and awareness about Crohn's disease and ulcerative colitis

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

Thrombogenics issues business update and half year results

AVANIR raises funds to develop and commercialize Zenvia for PBA

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

IVD labeled staining reagents for manual and automated staining platforms from DBS

Anti-glycan antibody positivity observed in celiac disease

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Research reveals that diarrheal bacteria can cause colon cancers

How to make hybridoma-based antibody discovery more efficient eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News